Cannabidiol/tetrahydrocannabinol - Axim Biotech

Drug Profile

Cannabidiol/tetrahydrocannabinol - Axim Biotech

Alternative Names: CBD/THC gum; MedChew 1401; MedChew 1502; MedChew 1503; MedChew 1504; MedChew GP; MedChew Rx; MedChew-RL; Tetrahydrocannabinol/cannabidiol - Axim Biotech

Latest Information Update: 09 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Axim Biotech
  • Class Analgesics; Antiemetics; Anxiolytics; Appetite stimulants; Cannabinoids; Muscle relaxants; Neuroprotectants; Phytotherapies
  • Mechanism of Action Cannabinoid receptor CB1 antagonists; Cannabinoid receptor CB2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Dementia; Pain; Parkinson's disease; Restless legs syndrome
  • Preclinical Postherpetic neuralgia

Most Recent Events

  • 03 Apr 2018 AXIM Biotech enters into a Memo of Understanding (MOU) for commericialisation of Canchew and Medchew in South Korea
  • 23 Jan 2018 Axim Biotech plans a clinical trial for Pain (pain and spasticity associated with Multiple sclerosis) in Netherlands
  • 23 Jan 2018 Axim Biotech plans a phase I trial in volunteers in Netherlands
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top